Use Genmab A-S fundamentals concurrently with your other holdings, portfolios, and investing themes to protect against small markets fluctuations and to back test it against optimization strategy that fits your risk preferences. Analyze Themes
Genmab competes with CITIGROUP, AP MOELLER, AP MOELLER, AKBANK, and INPEX. Its solutions in development include Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia, nonHodgkin?s lymphoma, diffuse large Bcell lymphoma, Waldenstrom?s macroglobulinemia, rheumatoid arthritis, and relapsing remitting multiple sclerosis; Zalutumumab, a human antibody that targets the epidermal growth factor receptor; and Daratumumab, a human antibody to target the CD38 molecule expressed on the surface of multiple myeloma tumor cells. Genmab A/S?s other clinical programs comprise RG4930 that is in phase II development for asthma targeting OX40L; and RG1512 targeting Pselectin, which is in phase II study for treatment of cardiovascular diseases. Its preclinical solutions include HuMaxTF ADC, HuMaxcMet, HuMaxTF ADC, HuMaxHer2, and HuMaxCD74 ADC for the treatment of cancer. Genmab A/S has collaboration agreements with GlaxoSmithKline to codevelop and commercialize ofatumumab; Roche to conduct clinical studies with RG4930 and RG1512 antibodies; H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system; and Seattle Genetics, Inc. for the development of HuMaxTF, an antibodydrug conjugate. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory